Who is sponsoring NCT00753324?

NCT00753324 is sponsored by University of North Carolina, Chapel Hill.

What condition does NCT00753324 study?

NCT00753324 studies HIV Infections.

What drugs are being tested in NCT00753324?

Interventions: Routine three-drug antiretroviral prophylaxis.

What is the status of NCT00753324?

NCT00753324 is currently COMPLETED.

Last reviewed 2016-03-25 · How we verify

Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia (Impact of HAART to Prevent Pediatric AIDS in Rural Zambia).

NCT00753324 Phase 4 COMPLETED

The investigators will enroll a cohort of HIV-infected pregnant women accessing PMTCT services, to better understand the incremental benefits (e.g. reduction in HIV transmission, improvements in HIV-free survival) and risks (e.g. drug toxicities) of the routine HAART strategy, in comparison to HIV-infected pregnant women accessing the Zambian Standard of Care services. The investigators will test the hypothesis that routine use of HAART produces significant reductions in HIV transmission rates, with only minimal side effects.

Details

Lead sponsor	University of North Carolina, Chapel Hill
Phase	Phase 4
Status	COMPLETED
Enrolment	284
Start date	2009-05
Completion	2012-01

Conditions

HIV Infections

Interventions

Routine three-drug antiretroviral prophylaxis

Primary outcomes

HIV Infection — 12 months

Countries

Zambia